Jennifer Arnold, MD

Jennifer Arnold, MD

Assistant Professor, Neurology
Neuroscience Institute
Language:
English

    About me

    Gender

    Female

    Education & training

    Positions
    Neurologist
    Medical School
    MD, University of Illinois
    Doctorate Degree
    Ph.D. Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign
    Undergraduate Degree
    BS Biology, Southeast Missouri State University
    Residency
    Neurology, University of Michigan
    Fellowship
    Neurodegenerative Diseases, University of Michigan

    Clinical trials

    Trial
    Neurology

    A 6-month (stage 1) & 18-month (stage 2) prospective, randomized, placebo-controlled, doubleblind dual clinical trial investigating efficacy and safety of buntanetap in treating participants with early Alzheimer’s disease

    Active recruiting
    In this study, the safety and efficacy of buntanetap will be assessed in a diverse population of early AD participants via a randomized, double-blind, placebo-controlled, multicenter Phase 3 trial.
    Contact: Stephanie Kohlrus 217-545-3013
    Trial
    Neurology

    A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild to Moderate Alzheimer’s Disease (MINDSET 2)

    Active recruiting
    The purpose of this research is to learn if the experimental study drug KarXT + KarX-EC works to treat thinking and memory problems as well as improve overall function in people with Alzheimer’s disease (AD).
    Contact: Mercedes Bryant 217-545-6829
    Trial
    Neurology

    ADCS Benfo: A Seamless Phase 2A-Phase 2B Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients with Early Alzheimer’s Disease (BenfoTeam)

    Active recruiting
    The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine, to determine whether it delays or slows the progression of the symptoms of early Alzheimer’s disease.
    Contact: Stephanie Kohlrus 217-545-3013
    Trial
    Neurology

    Athira: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Evaluate Safety and Efficacy of ATH-1017 Treatment in Alzheimer’s Dementia Patients

    Active recruiting

    ATH-1017-AD-201: The purpose of this study is to compare the effects, good or bad, of ATH-1017 on patients with mild to moderate Alzheimer's Disease.

    Contact: Stephanie Kohlrus 217-545-3013